These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32550584)

  • 1. Optimization of the rat digit abduction score (DAS) assay: Evaluation of botulinum neurotoxin activity in the gastrocnemius lateralis, peronei, and extensor digitorum longus.
    Cornet S; Périer C; Kalinichev M
    Toxicon X; 2020 Jun; 6():100029. PubMed ID: 32550584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WITHDRAWN: Optimization of the rat digit abduction score (DAS) assay: Evaluation of botulinum neurotoxin activity in the gastrocnemius lateralis, peronei, and extensor digitorum longus.
    Cornet S; Périer C; Kalinichev M
    Toxicon; 2020 Feb; ():. PubMed ID: 32113789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats.
    Cornet S; Périer C; Wagner S; Andriambeloson E; Pouzet B; Kalinichev M
    Toxicon X; 2020 Sep; 7():100041. PubMed ID: 32550595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
    Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo.
    Donald S; Elliott M; Gray B; Hornby F; Lewandowska A; Marlin S; Favre-Guilmard C; Périer C; Cornet S; Kalinichev M; Krupp J; Fonfria E
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00446. PubMed ID: 30519475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
    Morbiato L; Carli L; Johnson EA; Montecucco C; Molgó J; Rossetto O
    Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
    Adler M; Macdonald DA; Sellin LC; Parker GW
    Toxicon; 1996 Feb; 34(2):237-49. PubMed ID: 8711757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M; Keller JE; Sheridan RE; Deshpande SS
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.
    Elliott M; Maignel J; Liu SM; Favre-Guilmard C; Mir I; Farrow P; Hornby F; Marlin S; Palan S; Beard M; Krupp J
    PLoS One; 2017; 12(10):e0185628. PubMed ID: 28982136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
    Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
    Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
    Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
    Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ouabain exacerbates botulinum neurotoxin-induced muscle paralysis via progression of muscle atrophy in mice.
    Fujikawa R; Muroi Y; Unno T; Ishii T
    J Toxicol Sci; 2010 Dec; 35(6):795-805. PubMed ID: 21139329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
    Kim SB; Ban B; Jung KS; Yang GH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabrication, characterization and evaluation of a new designed botulinum toxin-cell penetrating peptide nanoparticulate complex.
    Ravari NS; Sheikhlou MG; Goodarzi N; Kharazian B; Amini M; Atyabi F; Nasrollahi SA; Dinarvand R
    Daru; 2023 Jun; 31(1):1-12. PubMed ID: 37209247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
    Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
    Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-based interspecies interpretation of botulinum neurotoxin type A on muscle-contraction inhibition.
    Ryu HJ; Kwak S; Park M; Yun HY
    Biopharm Drug Dispos; 2024 Jul; ():. PubMed ID: 39031599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.
    Brown M; Nicholson G; Ardila MC; Satorius A; Broide RS; Clarke K; Hunt T; Francis J
    J Neural Transm (Vienna); 2013 Feb; 120(2):291-8. PubMed ID: 22842675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of endurance training on oestrogen receptor alpha expression in different rat skeletal muscle type.
    Lemoine S; Granier P; Tiffoche C; Berthon PM; Thieulant ML; Carré F; Delamarche P
    Acta Physiol Scand; 2002 Jul; 175(3):211-7. PubMed ID: 12100360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.
    Rupp D; Nicholson G; Canty D; Wang J; Rhéaume C; Le L; Steward LE; Washburn M; Jacky BP; Broide RS; Philipp-Dormston WG; Brin MF; Brideau-Andersen A
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.